William Chase Net Worth

The estimated Net Worth of William J Chase is at least $36.7 Million dollars as of 26 June 2019. Mr. Chase owns over 30,400 units of AbbVie stock worth over $14,071,120 and over the last 7 years he sold ABBV stock worth over $13,909,612. In addition, he makes $8,724,790 as Executive Vice President – Finance and Administration at AbbVie.

Mr. Chase ABBV stock SEC Form 4 insider trading

William has made over 10 trades of the AbbVie stock since 2013, according to the Form 4 filled with the SEC. Most recently he bought 30,400 units of ABBV stock worth $2,045,920 on 26 June 2019.

The largest trade he’s ever made was selling 70,928 units of AbbVie stock on 28 February 2018 worth over $8,311,343. On average, William trades about 10,793 units every 106 days since 2013. As of 26 June 2019 he still owns at least 169,552 units of AbbVie stock.

You can see the complete history of Mr. Chase stock trades at the bottom of the page.

William Chase biography

William J. Chase serves as Executive Vice President – Finance and Administration of the Company. He served as Abbott’s Vice President, Licensing and Acquisitions from 2010 to 2012, as Vice President, Treasurer from 2007 to 2010, and as Divisional Vice President, Controller of Abbott International from 2004 to 2007. Mr. Chase joined Abbott in 1989.

What is the salary of William Chase?

As the Executive Vice President – Finance and Administration of AbbVie, the total compensation of William Chase at AbbVie is $8,724,790. There are 3 executives at AbbVie getting paid more, with Richard Gonzalez having the highest compensation of $21,271,900.

How old is William Chase?

William Chase is 51, he’s been the Executive Vice President – Finance and Administration of AbbVie since 2018. There are 15 older and 5 younger executives at AbbVie. The oldest executive at AbbVie, Inc. is Edward Liddy, 73, who is the Independent Director.

What’s William Chase’s mailing address?

William’s mailing address filed with the SEC is 1 N. WAUKEGAN ROAD, , NORTH CHICAGO, IL, 60064.

Insider trading at AbbVie

Over the last 7 years, insiders at AbbVie have traded over $114,130,047 worth of AbbVie stock and bought 207,390 units worth $13,938,118 . The most active insider traders include Richard A Gonzalez, Frederick H Waddell, and Glenn F Tilton. On average, AbbVie executives and independent directors trade stock every 21 days with the average trade being worth of $2,604,067. The most recent stock trade was executed by Timothy J. Richmond on 27 September 2019, trading 15,515 units of ABBV stock currently worth $1,163,935.

What does AbbVie do?

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson’s disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

What does AbbVie’s logo look like?

Complete history of Mr. Chase stock trades at AbbVie

AbbVie executives and stock owners

AbbVie executives and other stock owners filed with the SEC include:

  • Richard Gonzalez, Chairman of the Board, Chief Executive Officer
  • Laura Schumacher, Vice Chairman, External Affairs and Chief Legal Officer
  • Carlos Alban, Vice Chairman, Chief Commercial Officer
  • William Chase, Executive Vice President – Finance and Administration
  • Michael Severino, President, Vice Chairman
  • Timothy Richmond, Chief Human Resource Officer, Executive Vice President
  • Robert Michael, Chief Financial Officer, Senior Vice President
  • Glenn Tilton, Lead Independent Director
  • Robert Alpern, Independent Director
  • Edward Rapp, Independent Director
  • Frederick Waddell, Independent Director
  • Melody Meyer, Independent Director
  • William Burnside, Independent Director
  • Roxanne Austin, Independent Director
  • Brett Hart, Independent Director
  • Edward Liddy, Independent Director
  • Rebecca Roberts, Independent Director
  • Brian Durkin, Vice President, Controller
  • Jeffrey Stewart, Senior Vice President, U.S. Commercial Operations
  • Nicholas Donoghoe, Senior Vice President – Enterprise Innovation
  • Azita Saleki-Gerhardt, Executive Vice President – Operations
  • Henry Gosebruch, Executive Vice President, Chief Strategy Officer
  • Thomas A. Hurwich, VP, Controller
  • Roy S Roberts, Director
  • Laboratories Abbott, 10% owner
  • John M. Leonard, SVP, Chief Scientific Officer